{
    "info": {
        "nct_id": "NCT04639466",
        "official_title": "Phase 1/2 Dose Escalation Study To Evaluate the Safety and Biologically Effective Dose of GEO-CM04S1, a Synthetic MVA-based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers",
        "inclusion_criteria": "* PHASE I: Documented informed consent of the participant\n* PHASE I: Age: >= 18 years and < 55 years\n* PHASE I: Ability to read and understand English, Spanish, or Mandarin for consenting\n* PHASE I: Platelets >= 100,000/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: White blood cells (WBCs) 3,600-10,100/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Total bilirubin < 1.1 x upper limit of normal (ULN) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Aspartate aminotransferase (AST) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Alanine aminotransferase (ALT) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Alkaline phosphatase (AP) < 1.1 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Blood urea nitrogen (BUN) < 1.25 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Creatinine less than or equal to the ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Sodium 137-145 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Potassium 3.5-5.1 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Carbon dioxide 22-30 mmol/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Glucose 80-128 mg/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Albumin 3.5-5.0 g/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Hemoglobin (HGB) > 10.5 gm/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Hematocrit (Hct) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n\n  * For females: 34.5-44.6 %\n  * For males: 37.6-47.2 %\n* PHASE I: Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n\n  * If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed\n* PHASE I: History negative for COVID-19 and nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n\n  * Baseline SARS-CoV2serologic test will be performed at TGen using the InBios assay; the result will not be required for eligibility\n* PHASE I: A documented electrocardiogram (ECG) and cardiac troponin must be within normal institutional limits in the past 30 days; \"normal ECG with sinus tachycardia\" or \"normal ECG with sinus bradycardia\" is allowable based on a history of absent cardiac/exercise related symptoms as determined by the principal investigator (P.I.) in consultation with a senior staff cardiologist (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE I: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* PHASE I: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\n* PHASE II: Prior COVID-19 mRNA vaccination with EUA or FDA-approved vaccine, >= 6 months prior\n* PHASE II: ECOG performance score 0-1\n* PHASE II: Documented informed consent of the participant\n* PHASE II: Age: >= 18 years\n* PHASE II: Platelets >= 100,000/mm^3 (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: WBCs 3,600-10,100/mm^3 (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: Total bilirubin < 1.1 X ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: AST < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: ALT < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: AP < 1.1 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: BUN < 1.25 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: Creatinine less than or equal to the ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: Sodium 137-145 mEq/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: Potassium 3.5-5.1 mEq/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: Carbon dioxide 22-30 mmol/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: Glucose 80-128 mg/dL (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: Albumin 3.5-5.0 g/dL (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: HGB > 10.5 gm/dL (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n* PHASE II: Hematocrit (Hct) (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n\n  * For females: 34.5-44.6 %\n  * For males: 37.6-47.2 %\n* PHASE II: Seronegative for HIV Ag/Ab combo, HCV, active HBV (Surface Antigen Negative) (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n\n  * If positive, hepatitis C RNA quantitation must be performed\n* PHASE II: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)\n\n  * If the urine pregnancy test is inconclusive a serum pregnancy test will be required\n* PHASE II: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the booster\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
        "exclusion_criteria": "* PHASE I: Participants at increased risk of exposure to SARS-CoV-2, such as patient-facing health care workers and emergency responders are excluded\n* PHASE I: Participants who would be at higher risk for severe COVID-19 according to known risk factors are excluded e.g. type 2 diabetes, obesity (body mass index [BMI] >= 35), congestive heart failure (New York Heart Association class >= I), history of coronary artery disease, or chronic obstructive pulmonary disease\n* PHASE I: Participants using investigational or licensed agents that may prevent or treat SARS-CoV-2 are excluded\n* PHASE I: Participants are excluded, who have any history of allergic diatheses as defined by a history of asthma, anaphylaxis, or generalized urticaria, or by daily use of antihistamines, episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium\n* PHASE I: Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk\n* PHASE I: Surgery in past 6 months that required general anesthesia. Minor procedures, such as dental surgery and superficial diagnostic biopsies, are permitted\n* PHASE I: Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.\n* PHASE I: Participants who have had a live vaccine =< 30 days prior to administration of study vaccine or subjects who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine). Flu shots are allowed > 2 weeks before the first injection and > 2 weeks post 2nd injection\n* PHASE I: Treatment with medication for high cholesterol or other lipid abnormality. Prophylactic medication is acceptable\n* PHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* PHASE I: History of adverse event with a prior smallpox vaccination\n* PHASE I: Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired, or for which this study would pose a danger to him/herself or about which the P.I., in evaluating the subject for eligibility, determines that this exclusion is appropriate\n* PHASE I: Participants are excluded who have history of cancer other than basal cell skin cancer, or any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc. as determined by the P.I.)\n* PHASE I: Participants with severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded but those on effective medication (less than one migraine per month) are allowed to enroll\n* PHASE I: History of heart disease, e.g. previous treated arrhythmia or myocardial infarction\n* PHASE I: Horizontal positioning- induced or activities of normal living exercise-induced shortness of breath\n* PHASE I: History of stroke or claudication\n* PHASE I: Any of the following cardiac findings of ECG abnormality: 1) conduction disturbance (complete left or right bundle branch block, intraventricular conduction disturbance with QRS > 120 ms, atrioventricular block [AV] block of any degree, and corrected QT [QTc] prolongation > 450 msec for men and > 460 msec for women); 2) repolarization (ST segment or T wave) abnormality; 3) significant atrial or ventricular arrhythmia, including frequent ectopy (e.g., 2 premature ventricular contractions in a row); and 4) evidence of past myocardial infarction.\n* PHASE I: Poxvirus vaccine in the last 12 months\n* PHASE I: Any MVA vaccine or poxvirus vaccine in the last 12 months\n* PHASE I: Any previous SARS-CoV-2 vaccine\n* PHASE I: History of or prior treatment for diabetes type 1 or diabetes type 2; BMI < 18 or > 35. BMI can be rounded to the nearest integer\n* PHASE I: Clinically significant uncontrolled illness\n* PHASE I: Active infection requiring treatment\n* PHASE I: Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection\n* PHASE I: Diagnosis which has been associated with immunodeficiency\n* PHASE I: Females only: Pregnant or breastfeeding\n* PHASE I: Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 6 weeks after the second and last dose of vaccine\n* PHASE I: Participants who are employed by or are a student at City of Hope and are in a chain of command that reports directly to persons listed on the protocol as principal investigator or co-investigators; or are relatives or partners of the investigators\n* PHASE I: Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures\n* PHASE I: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)\n* PHASE I: Anyone considered to be in a vulnerable population as defined in 45 CFR 46.111 (a)(3) and 45 CFR 46, Subparts B-D\n* PHASE II: Participants who would be at higher risk for severe COVID-19 according to known risk factors are excluded e.g. type 2 diabetes, obesity (BMI > 35), congestive heart failure (New York Heart Association Class >= I), history of coronary artery disease, cardiomyopathies, sickle cell disease, smoking, chronic kidney disease, immunocompromised state from solid organ transplant, or chronic obstructive pulmonary disease, or active cancers other than basal cell skin cancer at discretion of the investigator.\n* PHASE II: Participants are excluded, who have any history of allergic diatheses as defined by a history of asthma, anaphylaxis, or generalized urticaria, episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium\n* PHASE II: Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk\n* PHASE II: Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.\n* PHASE II: Participants who have had a live vaccine =< 30 days prior to administration of study vaccine or participants who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine). Flu shots are allowed > 2 weeks before the booster injection and > 2 weeks post booster injection\n* PHASE II: Intensive cytotoxic therapies, B- or T-cell depleting therapies, or checkpoint inhibitors within 30 days of enrollment\n* PHASE II: Systemic corticosteroids required for chronic conditions at doses > 0.5 mg/kg/day prednisone equivalent within 14 days of enrollment\n* PHASE II: Previously received a COVID-19 vaccine booster injection\n* PHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* PHASE II: History (suspected or confirmed) of myocarditis or pericarditis\n* PHASE II: History of adverse event with a prior smallpox vaccination\n* PHASE II: Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired, or for which this study would pose a danger to him/herself or about which the P.I., in evaluating the participant for eligibility, determines that this exclusion is appropriate.\n* PHASE II: Participants are excluded who have any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc. as determined by the P.I.)\n* PHASE II: Participants with severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded but those on effective medication (less than one migraine per month) are allowed to enroll.\n* PHASE II: History of heart disease, e.g. previous treated arrhythmia or myocardial infarction\n* PHASE II: History of stroke or claudication.\n* PHASE II: Any MVA vaccine or poxvirus vaccine in the last 12 months;\n* PHASE II: Clinically significant uncontrolled illness\n* PHASE II: Active infection requiring treatment\n* PHASE II: Females only: Pregnant or breastfeeding\n* PHASE II: Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 60 days after the second and last dose of vaccine;\n* PHASE II: Persons listed on the protocol as Principal Investigator or Co-Investigators, and those who have disclosed a Conflict of Interest regarding COH04S1. Prospective participants who are COH employees reporting to study personnel conducting consent for the Phase 2 study must be consented by other consenting personnel to ensure no coercion. COH employees who would be involved in a quality or risk management function (auditing or monitoring) or the Study Management Team (SMT) with respect to this trial are ineligible.\n* PHASE II: Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns with clinical study procedures.\n\nNoncompliance\n\n* PHASE II: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).\n* PHASE II: Anyone considered to be in a vulnerable population as defined in 45 CFR §46.111 (a)(3) and 45 CFR §46, Subparts B-D",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* PHASE II: ALT < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "ALT < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "ALT (alanine aminotransferase) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "ALT (alanine aminotransferase) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ALT < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "ALT (alanine aminotransferase) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "ALT (alanine aminotransferase) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Potassium 3.5-5.1 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Potassium 3.5-5.1 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3.5,
                                        "unit": "mEq/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5.1,
                                        "unit": "mEq/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Potassium 3.5-5.1 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Potassium 3.5-5.1 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3.5,
                                        "unit": "mEq/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5.1,
                                        "unit": "mEq/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Potassium 3.5-5.1 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Documented informed consent of the participant",
                "criterions": [
                    {
                        "exact_snippets": "Documented informed consent of the participant",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Documented informed consent of the participant",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Albumin 3.5-5.0 g/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Albumin 3.5-5.0 g/dL (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "albumin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3.5,
                                        "unit": "g/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "g/dL"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Albumin 3.5-5.0 g/dL (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "albumin level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Albumin 3.5-5.0 g/dL (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "albumin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3.5,
                                        "unit": "g/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "g/dL"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Albumin 3.5-5.0 g/dL (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "albumin level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Carbon dioxide 22-30 mmol/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Carbon dioxide 22-30 mmol/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "carbon dioxide",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 22,
                                        "unit": "mmol/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "mmol/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Carbon dioxide 22-30 mmol/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "carbon dioxide",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Carbon dioxide 22-30 mmol/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "carbon dioxide",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 22,
                                        "unit": "mmol/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "mmol/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Carbon dioxide 22-30 mmol/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "carbon dioxide",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: History negative for COVID-19 and nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "History negative for COVID-19",
                        "criterion": "COVID-19 history",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "SARS-CoV2 nasopharyngeal test",
                        "requirement": {
                            "requirement_type": "test_status",
                            "expected_value": "pending"
                        }
                    },
                    {
                        "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "SARS-CoV2 nasopharyngeal test",
                        "requirement": {
                            "requirement_type": "test_location",
                            "expected_value": "City of Hope (COH)"
                        }
                    },
                    {
                        "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "SARS-CoV2 nasopharyngeal test",
                        "requirement": {
                            "requirement_type": "sample_type",
                            "expected_value": "nasal wash"
                        }
                    },
                    {
                        "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "SARS-CoV2 nasopharyngeal test",
                        "requirement": {
                            "requirement_type": "test_method",
                            "expected_value": "Diasorin Simplexa"
                        }
                    },
                    {
                        "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "SARS-CoV2 nasopharyngeal test",
                        "requirement": {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to day 0 of protocol therapy"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History negative for COVID-19",
                        "criterion": "COVID-19 history",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                                "criterion": "SARS-CoV2 nasopharyngeal test",
                                "requirement": {
                                    "requirement_type": "test_status",
                                    "expected_value": "pending"
                                }
                            },
                            {
                                "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                                "criterion": "SARS-CoV2 nasopharyngeal test",
                                "requirement": {
                                    "requirement_type": "test_location",
                                    "expected_value": "City of Hope (COH)"
                                }
                            },
                            {
                                "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                                "criterion": "SARS-CoV2 nasopharyngeal test",
                                "requirement": {
                                    "requirement_type": "sample_type",
                                    "expected_value": "nasal wash"
                                }
                            },
                            {
                                "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                                "criterion": "SARS-CoV2 nasopharyngeal test",
                                "requirement": {
                                    "requirement_type": "test_method",
                                    "expected_value": "Diasorin Simplexa"
                                }
                            },
                            {
                                "exact_snippets": "nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                                "criterion": "SARS-CoV2 nasopharyngeal test",
                                "requirement": {
                                    "requirement_type": "time_window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "days prior to day 0 of protocol therapy"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy",
                "criterions": [
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy",
                        "criterion": "birth control or abstinence during and after study",
                        "requirement": {
                            "requirement_type": "agreement to use effective birth control or abstain from heterosexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy",
                        "criterion": "birth control or abstinence during and after study",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy",
                        "criterion": "birth control or abstinence during and after study",
                        "requirement": {
                            "requirement_type": "agreement to use effective birth control or abstain from heterosexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy",
                        "criterion": "birth control or abstinence during and after study",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Glucose 80-128 mg/dL (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Glucose 80-128 mg/dL",
                        "criterion": "glucose level",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 80,
                                        "unit": "mg/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 128,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Glucose 80-128 mg/dL",
                        "criterion": "glucose level",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 80,
                                        "unit": "mg/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 128,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: WBCs 3,600-10,100/mm^3 (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "WBCs 3,600-10,100/mm^3",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3600,
                                        "unit": "mm^3"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10100,
                                        "unit": "mm^3"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "WBCs 3,600-10,100/mm^3",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3600,
                                        "unit": "mm^3"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10100,
                                        "unit": "mm^3"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Alanine aminotransferase (ALT) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Hematocrit (Hct) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Hematocrit (Hct) (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hematocrit (Hct)",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hematocrit (Hct) (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hematocrit (Hct)",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Documented informed consent of the participant",
                "criterions": [
                    {
                        "exact_snippets": "Documented informed consent of the participant",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Documented informed consent of the participant",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Total bilirubin < 1.1 X ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin < 1.1 X ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.1,
                                "unit": "X ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Total bilirubin < 1.1 X ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.1,
                                "unit": "X ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Sodium 137-145 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Sodium 137-145 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "sodium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 137,
                                        "unit": "mEq/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 145,
                                        "unit": "mEq/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Sodium 137-145 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "sodium level",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Sodium 137-145 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "sodium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 137,
                                        "unit": "mEq/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 145,
                                        "unit": "mEq/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Sodium 137-145 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "sodium level",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: White blood cells (WBCs) 3,600-10,100/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "White blood cells (WBCs) 3,600-10,100/mm^3 (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3600,
                                        "unit": "mm^3"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10100,
                                        "unit": "mm^3"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "White blood cells (WBCs) 3,600-10,100/mm^3 (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "White blood cells (WBCs) 3,600-10,100/mm^3 (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3600,
                                        "unit": "mm^3"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10100,
                                        "unit": "mm^3"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "White blood cells (WBCs) 3,600-10,100/mm^3 (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the booster",
                "criterions": [
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the booster",
                        "criterion": "birth control or abstinence during study",
                        "requirement": {
                            "requirement_type": "agreement to use effective birth control or abstain from heterosexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the booster",
                        "criterion": "birth control or abstinence during study",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "course of the study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "weeks after the booster"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the booster",
                        "criterion": "birth control or abstinence during study",
                        "requirement": {
                            "requirement_type": "agreement to use effective birth control or abstain from heterosexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the booster",
                        "criterion": "birth control or abstinence during study",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "course of the study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "weeks after the booster"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Creatinine less than or equal to the ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine less than or equal to the ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine less than or equal to the ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Creatinine less than or equal to the ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine less than or equal to the ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Age: >= 18 years and < 55 years",
                "criterions": [
                    {
                        "exact_snippets": "Age: >= 18 years and < 55 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 55,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age: >= 18 years and < 55 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 55,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* For males: 37.6-47.2 %",
                "criterions": [
                    {
                        "exact_snippets": "For males: 37.6-47.2 %",
                        "criterion": "hematocrit (for males)",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 37.6,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 47.2,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "For males: 37.6-47.2 %",
                        "criterion": "hematocrit (for males)",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 37.6,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 47.2,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* For females: 34.5-44.6 %",
                "criterions": [
                    {
                        "exact_snippets": "For females: 34.5-44.6 %",
                        "criterion": "[unspecified laboratory value or measurement for females]",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 34.5,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 44.6,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "For females: 34.5-44.6 %",
                        "criterion": "[unspecified laboratory value or measurement for females]",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 34.5,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 44.6,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* For females: 34.5-44.6 %",
                "criterions": [
                    {
                        "exact_snippets": "For females: 34.5-44.6 %",
                        "criterion": "females' value (unspecified parameter)",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 34.5,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 44.6,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "For females: 34.5-44.6 %",
                        "criterion": "females' value (unspecified parameter)",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 34.5,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 44.6,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Age: >= 18 years",
                "criterions": [
                    {
                        "exact_snippets": "Age: >= 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age: >= 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Hematocrit (Hct) (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Hematocrit (Hct) (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hematocrit (Hct)",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hematocrit (Hct) (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hematocrit (Hct)",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Platelets >= 100,000/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Platelets >= 100,000/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets >= 100,000/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets >= 100,000/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets >= 100,000/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Glucose 80-128 mg/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Glucose 80-128 mg/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "glucose level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 80,
                                        "unit": "mg/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 128,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Glucose 80-128 mg/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "glucose level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 80,
                                        "unit": "mg/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 128,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)",
                "criterions": [
                    {
                        "exact_snippets": "not being surgically sterilized (men and women)",
                        "criterion": "surgical sterilization status",
                        "requirement": {
                            "requirement_type": "sterilization",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "have not been free from menses for > 1 year (women only)",
                        "criterion": "menstrual status",
                        "requirement": {
                            "requirement_type": "free from menses duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "have not been free from menses for > 1 year (women only)",
                        "criterion": "menstrual status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "not being surgically sterilized (men and women)",
                        "criterion": "surgical sterilization status",
                        "requirement": {
                            "requirement_type": "sterilization",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "have not been free from menses for > 1 year (women only)",
                                "criterion": "menstrual status",
                                "requirement": {
                                    "requirement_type": "sex",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "exact_snippets": "have not been free from menses for > 1 year (women only)",
                                "criterion": "menstrual status",
                                "requirement": {
                                    "requirement_type": "free from menses duration",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "year"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: BUN < 1.25 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "BUN < 1.25 x ULN",
                        "criterion": "blood urea nitrogen (BUN) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.25,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "BUN < 1.25 x ULN",
                        "criterion": "blood urea nitrogen (BUN) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.25,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: AST < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "AST < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "AST (aspartate aminotransferase) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "AST (aspartate aminotransferase) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "AST < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "AST (aspartate aminotransferase) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "AST (aspartate aminotransferase) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Creatinine less than or equal to the ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine less than or equal to the ULN",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Creatinine less than or equal to the ULN",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Albumin 3.5-5.0 g/dL (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Albumin 3.5-5.0 g/dL",
                        "criterion": "albumin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3.5,
                                        "unit": "g/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "g/dL"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Albumin 3.5-5.0 g/dL",
                        "criterion": "albumin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3.5,
                                        "unit": "g/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "g/dL"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)",
                "criterions": [
                    {
                        "exact_snippets": "not being surgically sterilized (men and women)",
                        "criterion": "surgical sterilization status",
                        "requirement": {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "have not been free from menses for > 1 year (women only)",
                        "criterion": "menstrual status (women only)",
                        "requirement": {
                            "requirement_type": "free from menses duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "have not been free from menses for > 1 year (women only)",
                        "criterion": "menstrual status (women only)",
                        "requirement": {
                            "requirement_type": "free from menses",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "not being surgically sterilized (men and women)",
                        "criterion": "surgical sterilization status",
                        "requirement": {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "have not been free from menses for > 1 year (women only)",
                                "criterion": "menstrual status (women only)",
                                "requirement": {
                                    "requirement_type": "free from menses duration",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "year"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "have not been free from menses for > 1 year (women only)",
                                "criterion": "menstrual status (women only)",
                                "requirement": {
                                    "requirement_type": "free from menses",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Hemoglobin (HGB) > 10.5 gm/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin (HGB) > 10.5 gm/dL (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hemoglobin (HGB) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10.5,
                                "unit": "gm/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hemoglobin (HGB) > 10.5 gm/dL (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hemoglobin (HGB) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin (HGB) > 10.5 gm/dL (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hemoglobin (HGB) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10.5,
                                "unit": "gm/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hemoglobin (HGB) > 10.5 gm/dL (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hemoglobin (HGB) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Carbon dioxide 22-30 mmol/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Carbon dioxide 22-30 mmol/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "carbon dioxide level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 22,
                                        "unit": "mmol/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "mmol/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Carbon dioxide 22-30 mmol/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "carbon dioxide level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Carbon dioxide 22-30 mmol/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "carbon dioxide level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 22,
                                        "unit": "mmol/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "mmol/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Carbon dioxide 22-30 mmol/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "carbon dioxide level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Sodium 137-145 mEq/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Sodium 137-145 mEq/L (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "serum sodium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 137,
                                        "unit": "mEq/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 145,
                                        "unit": "mEq/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Sodium 137-145 mEq/L (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "serum sodium level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Sodium 137-145 mEq/L (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "serum sodium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 137,
                                        "unit": "mEq/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 145,
                                        "unit": "mEq/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Sodium 137-145 mEq/L (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "serum sodium level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo",
                        "criterion": "HIV antigen/antibody status",
                        "requirement": {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Seronegative for ... hepatitis C virus (HCV)",
                        "criterion": "hepatitis C virus (HCV) status",
                        "requirement": {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active hepatitis B virus (HBV) (surface antigen negative)",
                        "criterion": "hepatitis B virus (HBV) surface antigen status",
                        "requirement": {
                            "requirement_type": "surface antigen negativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to day 0 of protocol therapy",
                        "criterion": "timing of serology tests",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to day 0 of protocol therapy"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo",
                        "criterion": "HIV antigen/antibody status",
                        "requirement": {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Seronegative for ... hepatitis C virus (HCV)",
                        "criterion": "hepatitis C virus (HCV) status",
                        "requirement": {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active hepatitis B virus (HBV) (surface antigen negative)",
                        "criterion": "hepatitis B virus (HBV) surface antigen status",
                        "requirement": {
                            "requirement_type": "surface antigen negativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to day 0 of protocol therapy",
                        "criterion": "timing of serology tests",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to day 0 of protocol therapy"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Baseline SARS-CoV2serologic test will be performed at TGen using the InBios assay; the result will not be required for eligibility",
                "criterions": [
                    {
                        "exact_snippets": "Baseline SARS-CoV2 serologic test will be performed",
                        "criterion": "SARS-CoV2 serologic test",
                        "requirement": {
                            "requirement_type": "test performed",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Baseline SARS-CoV2 serologic test will be performed",
                        "criterion": "SARS-CoV2 serologic test",
                        "requirement": {
                            "requirement_type": "test performed",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* If the urine pregnancy test is inconclusive a serum pregnancy test will be required",
                "criterions": [
                    {
                        "exact_snippets": "urine pregnancy test is inconclusive",
                        "criterion": "urine pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "inconclusive"
                        }
                    },
                    {
                        "exact_snippets": "serum pregnancy test will be required",
                        "criterion": "serum pregnancy test",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "urine pregnancy test is inconclusive",
                    "criterion": "urine pregnancy test",
                    "requirement": {
                        "requirement_type": "result",
                        "expected_value": "inconclusive"
                    }
                },
                "then_criteria": {
                    "exact_snippets": "serum pregnancy test will be required",
                    "criterion": "serum pregnancy test",
                    "requirement": {
                        "requirement_type": "requirement",
                        "expected_value": true
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Platelets >= 100,000/mm^3 (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Platelets >= 100,000/mm^3",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets >= 100,000/mm^3",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Blood urea nitrogen (BUN) < 1.25 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Blood urea nitrogen (BUN) < 1.25 x ULN (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "blood urea nitrogen (BUN)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.25,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Blood urea nitrogen (BUN) < 1.25 x ULN (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "blood urea nitrogen (BUN)",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Blood urea nitrogen (BUN) < 1.25 x ULN (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "blood urea nitrogen (BUN)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.25,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Blood urea nitrogen (BUN) < 1.25 x ULN (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "blood urea nitrogen (BUN)",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Aspartate aminotransferase (AST) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: AP < 1.1 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "AP < 1.1 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "alkaline phosphatase (AP) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.1,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AP < 1.1 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "alkaline phosphatase (AP) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "AP < 1.1 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "alkaline phosphatase (AP) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.1,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AP < 1.1 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "alkaline phosphatase (AP) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Alkaline phosphatase (AP) < 1.1 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Alkaline phosphatase (AP) < 1.1 x ULN (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "alkaline phosphatase (AP) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.1,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Alkaline phosphatase (AP) < 1.1 x ULN (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "alkaline phosphatase (AP) level",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Alkaline phosphatase (AP) < 1.1 x ULN (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "alkaline phosphatase (AP) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.1,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Alkaline phosphatase (AP) < 1.1 x ULN (within 30 days prior to day 0 of protocol therapy",
                        "criterion": "alkaline phosphatase (AP) level",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Total bilirubin < 1.1 x upper limit of normal (ULN) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin < 1.1 x upper limit of normal (ULN) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.1,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin < 1.1 x upper limit of normal (ULN) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Total bilirubin < 1.1 x upper limit of normal (ULN) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.1,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin < 1.1 x upper limit of normal (ULN) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: HGB > 10.5 gm/dL (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "HGB > 10.5 gm/dL (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hemoglobin (HGB) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10.5,
                                "unit": "gm/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "HGB > 10.5 gm/dL (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hemoglobin (HGB) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "HGB > 10.5 gm/dL (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hemoglobin (HGB) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10.5,
                                "unit": "gm/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "HGB > 10.5 gm/dL (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "hemoglobin (HGB) level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have maximum age of 55 Years",
                "criterions": [
                    {
                        "exact_snippets": "maximum age of 55 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "maximum age of 55 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Potassium 3.5-5.1 mEq/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Potassium 3.5-5.1 mEq/L (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3.5,
                                        "unit": "mEq/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5.1,
                                        "unit": "mEq/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Potassium 3.5-5.1 mEq/L (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Potassium 3.5-5.1 mEq/L (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3.5,
                                        "unit": "mEq/L"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5.1,
                                        "unit": "mEq/L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Potassium 3.5-5.1 mEq/L (performed within 30 days prior to day 0 of protocol therapy",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "performed within 30 days prior to day 0 of protocol therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: ECOG performance score 0-1",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance score 0-1",
                        "criterion": "ECOG performance score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance score 0-1",
                        "criterion": "ECOG performance score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Seronegative for HIV Ag/Ab combo, HCV, active HBV (Surface Antigen Negative) (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Seronegative for HIV Ag/Ab combo",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Seronegative for ... HCV",
                        "criterion": "Hepatitis C virus infection",
                        "requirement": {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active HBV (Surface Antigen Negative)",
                        "criterion": "Hepatitis B virus infection",
                        "requirement": {
                            "requirement_type": "surface antigen negativity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Seronegative for HIV Ag/Ab combo",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Seronegative for ... HCV",
                        "criterion": "Hepatitis C virus infection",
                        "requirement": {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active HBV (Surface Antigen Negative)",
                        "criterion": "Hepatitis B virus infection",
                        "requirement": {
                            "requirement_type": "surface antigen negativity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* For males: 37.6-47.2 %",
                "criterions": [
                    {
                        "exact_snippets": "For males: 37.6-47.2 %",
                        "criterion": "hematocrit (for males)",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 37.6,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 47.2,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "For males: 37.6-47.2 %",
                        "criterion": "hematocrit (for males)",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 37.6,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 47.2,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* PHASE I: Diagnosis which has been associated with immunodeficiency",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosis which has been associated with immunodeficiency",
                        "criterion": "diagnosis associated with immunodeficiency",
                        "requirement": {
                            "requirement_type": "association",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Diagnosis which has been associated with immunodeficiency",
                    "criterion": "diagnosis associated with immunodeficiency",
                    "requirement": {
                        "requirement_type": "association",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: History of adverse event with a prior smallpox vaccination",
                "criterions": [
                    {
                        "exact_snippets": "History of adverse event with a prior smallpox vaccination",
                        "criterion": "adverse event with prior smallpox vaccination",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of adverse event with a prior smallpox vaccination",
                    "criterion": "adverse event with prior smallpox vaccination",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Previously received a COVID-19 vaccine booster injection",
                "criterions": [
                    {
                        "exact_snippets": "Previously received a COVID-19 vaccine booster injection",
                        "criterion": "COVID-19 vaccine booster injection",
                        "requirement": {
                            "requirement_type": "history of administration",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Previously received a COVID-19 vaccine booster injection",
                    "criterion": "COVID-19 vaccine booster injection",
                    "requirement": {
                        "requirement_type": "history of administration",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                "criterions": [
                    {
                        "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                        "criterion": "ability to comply with study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                    "criterion": "ability to comply with study procedures",
                    "requirement": {
                        "requirement_type": "ability",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                "criterions": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                        "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study agent",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                    "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study agent",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Any MVA vaccine or poxvirus vaccine in the last 12 months",
                "criterions": [
                    {
                        "exact_snippets": "Any MVA vaccine or poxvirus vaccine in the last 12 months",
                        "criterion": "MVA vaccine or poxvirus vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Any MVA vaccine or poxvirus vaccine in the last 12 months",
                    "criterion": "MVA vaccine or poxvirus vaccine administration",
                    "requirement": {
                        "requirement_type": "time since administration",
                        "expected_value": {
                            "operator": "<=",
                            "value": 12,
                            "unit": "months"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Surgery in past 6 months that required general anesthesia. Minor procedures, such as dental surgery and superficial diagnostic biopsies, are permitted",
                "criterions": [
                    {
                        "exact_snippets": "Surgery in past 6 months that required general anesthesia",
                        "criterion": "surgery with general anesthesia",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Surgery in past 6 months that required general anesthesia",
                        "criterion": "surgery with general anesthesia",
                        "requirement": {
                            "requirement_type": "requirement for general anesthesia",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Surgery in past 6 months that required general anesthesia",
                                "criterion": "surgery with general anesthesia",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Surgery in past 6 months that required general anesthesia",
                                "criterion": "surgery with general anesthesia",
                                "requirement": {
                                    "requirement_type": "requirement for general anesthesia",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Participants are excluded who have history of cancer other than basal cell skin cancer, or any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc. as determined by the P.I.)",
                "criterions": [
                    {
                        "exact_snippets": "history of cancer other than basal cell skin cancer",
                        "criterion": "history of cancer",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "no history of cancer other than basal cell skin cancer"
                        }
                    },
                    {
                        "exact_snippets": "any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc. as determined by the P.I.)",
                        "criterion": "condition that would preclude informed consent, consistent follow-up or compliance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "history of cancer other than basal cell skin cancer",
                        "criterion": "history of cancer",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "no history of cancer other than basal cell skin cancer"
                        }
                    },
                    {
                        "exact_snippets": "any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc. as determined by the P.I.)",
                        "criterion": "condition that would preclude informed consent, consistent follow-up or compliance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: History of stroke or claudication.",
                "criterions": [
                    {
                        "exact_snippets": "History of stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "claudication",
                        "criterion": "claudication",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "claudication",
                        "criterion": "claudication",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: History of or prior treatment for diabetes type 1 or diabetes type 2; BMI < 18 or > 35. BMI can be rounded to the nearest integer",
                "criterions": [
                    {
                        "exact_snippets": "History of or prior treatment for diabetes type 1 or diabetes type 2",
                        "criterion": "diabetes (type 1 or type 2)",
                        "requirement": {
                            "requirement_type": "history or prior treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "BMI < 18 or > 35. BMI can be rounded to the nearest integer",
                        "criterion": "BMI",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 18,
                                        "unit": ""
                                    },
                                    {
                                        "operator": ">",
                                        "value": 35,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of or prior treatment for diabetes type 1 or diabetes type 2",
                        "criterion": "diabetes (type 1 or type 2)",
                        "requirement": {
                            "requirement_type": "history or prior treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "BMI < 18 or > 35. BMI can be rounded to the nearest integer",
                        "criterion": "BMI",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 18,
                                        "unit": ""
                                    },
                                    {
                                        "operator": ">",
                                        "value": 35,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Intensive cytotoxic therapies, B- or T-cell depleting therapies, or checkpoint inhibitors within 30 days of enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Intensive cytotoxic therapies ... within 30 days of enrollment",
                        "criterion": "intensive cytotoxic therapies",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "B- or T-cell depleting therapies ... within 30 days of enrollment",
                        "criterion": "B-cell depleting therapies",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "B- or T-cell depleting therapies ... within 30 days of enrollment",
                        "criterion": "T-cell depleting therapies",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "checkpoint inhibitors within 30 days of enrollment",
                        "criterion": "checkpoint inhibitors",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Intensive cytotoxic therapies ... within 30 days of enrollment",
                        "criterion": "intensive cytotoxic therapies",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "B- or T-cell depleting therapies ... within 30 days of enrollment",
                        "criterion": "B-cell depleting therapies",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "B- or T-cell depleting therapies ... within 30 days of enrollment",
                        "criterion": "T-cell depleting therapies",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "checkpoint inhibitors within 30 days of enrollment",
                        "criterion": "checkpoint inhibitors",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Participants with severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded but those on effective medication (less than one migraine per month) are allowed to enroll",
                "criterions": [
                    {
                        "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                        "criterion": "severe migraine headaches",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "per month"
                            }
                        }
                    },
                    {
                        "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                        "criterion": "severe migraine headaches",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "in the past 6 months"
                        }
                    },
                    {
                        "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                        "criterion": "severe migraine headaches",
                        "requirement": {
                            "requirement_type": "preventive medication requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "those on effective medication (less than one migraine per month) are allowed to enroll",
                        "criterion": "migraine frequency on effective medication",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "per month"
                            }
                        }
                    },
                    {
                        "exact_snippets": "those on effective medication (less than one migraine per month) are allowed to enroll",
                        "criterion": "migraine frequency on effective medication",
                        "requirement": {
                            "requirement_type": "medication effectiveness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                                "criterion": "severe migraine headaches",
                                "requirement": {
                                    "requirement_type": "frequency",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "per month"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                                "criterion": "severe migraine headaches",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": "in the past 6 months"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                        "criterion": "severe migraine headaches",
                        "requirement": {
                            "requirement_type": "preventive medication requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "those on effective medication (less than one migraine per month) are allowed to enroll",
                                "criterion": "migraine frequency on effective medication",
                                "requirement": {
                                    "requirement_type": "frequency",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 1,
                                        "unit": "per month"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "those on effective medication (less than one migraine per month) are allowed to enroll",
                                "criterion": "migraine frequency on effective medication",
                                "requirement": {
                                    "requirement_type": "medication effectiveness",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Participants with severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded but those on effective medication (less than one migraine per month) are allowed to enroll.",
                "criterions": [
                    {
                        "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                        "criterion": "severe migraine headaches",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "per month"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                        "criterion": "severe migraine headaches",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                        "criterion": "severe migraine headaches",
                        "requirement": {
                            "requirement_type": "preventive medication requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "those on effective medication (less than one migraine per month) are allowed to enroll",
                        "criterion": "migraine frequency on effective medication",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 1,
                                        "unit": "per month"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                                "criterion": "severe migraine headaches",
                                "requirement": {
                                    "requirement_type": "frequency",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">",
                                                "value": 1,
                                                "unit": "per month"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                                "criterion": "severe migraine headaches",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded",
                        "criterion": "severe migraine headaches",
                        "requirement": {
                            "requirement_type": "preventive medication requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "those on effective medication (less than one migraine per month) are allowed to enroll",
                            "criterion": "migraine frequency on effective medication",
                            "requirement": {
                                "requirement_type": "frequency",
                                "expected_value": {
                                    "comparisons": [
                                        {
                                            "operator": "<",
                                            "value": 1,
                                            "unit": "per month"
                                        }
                                    ]
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Horizontal positioning- induced or activities of normal living exercise-induced shortness of breath",
                "criterions": [
                    {
                        "exact_snippets": "Horizontal positioning- induced ... shortness of breath",
                        "criterion": "shortness of breath",
                        "requirement": {
                            "requirement_type": "trigger",
                            "expected_value": "horizontal positioning"
                        }
                    },
                    {
                        "exact_snippets": "activities of normal living exercise-induced shortness of breath",
                        "criterion": "shortness of breath",
                        "requirement": {
                            "requirement_type": "trigger",
                            "expected_value": "activities of normal living"
                        }
                    },
                    {
                        "exact_snippets": "activities of normal living exercise-induced shortness of breath",
                        "criterion": "shortness of breath",
                        "requirement": {
                            "requirement_type": "trigger",
                            "expected_value": "exercise"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Horizontal positioning- induced ... shortness of breath",
                        "criterion": "shortness of breath",
                        "requirement": {
                            "requirement_type": "trigger",
                            "expected_value": "horizontal positioning"
                        }
                    },
                    {
                        "exact_snippets": "activities of normal living exercise-induced shortness of breath",
                        "criterion": "shortness of breath",
                        "requirement": {
                            "requirement_type": "trigger",
                            "expected_value": "activities of normal living"
                        }
                    },
                    {
                        "exact_snippets": "activities of normal living exercise-induced shortness of breath",
                        "criterion": "shortness of breath",
                        "requirement": {
                            "requirement_type": "trigger",
                            "expected_value": "exercise"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk",
                "criterions": [
                    {
                        "exact_snippets": "Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk",
                        "criterion": "condition posing infectious risk to study staff",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk",
                    "criterion": "condition posing infectious risk to study staff",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": false
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Participants who would be at higher risk for severe COVID-19 according to known risk factors are excluded e.g. type 2 diabetes, obesity (body mass index [BMI] >= 35), congestive heart failure (New York Heart Association class >= I), history of coronary artery disease, or chronic obstructive pulmonary disease",
                "criterions": [
                    {
                        "exact_snippets": "type 2 diabetes",
                        "criterion": "type 2 diabetes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "obesity (body mass index [BMI] >= 35)",
                        "criterion": "obesity",
                        "requirement": {
                            "requirement_type": "BMI",
                            "expected_value": {
                                "operator": ">=",
                                "value": 35,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "obesity (body mass index [BMI] >= 35)",
                        "criterion": "obesity",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure (New York Heart Association class >= I)",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure (New York Heart Association class >= I)",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "history of coronary artery disease",
                        "criterion": "history of coronary artery disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "chronic obstructive pulmonary disease",
                        "criterion": "chronic obstructive pulmonary disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "type 2 diabetes",
                        "criterion": "type 2 diabetes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "obesity (body mass index [BMI] >= 35)",
                                "criterion": "obesity",
                                "requirement": {
                                    "requirement_type": "BMI",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 35,
                                        "unit": ""
                                    }
                                }
                            },
                            {
                                "exact_snippets": "obesity (body mass index [BMI] >= 35)",
                                "criterion": "obesity",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "congestive heart failure (New York Heart Association class >= I)",
                                "criterion": "congestive heart failure",
                                "requirement": {
                                    "requirement_type": "NYHA class",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                }
                            },
                            {
                                "exact_snippets": "congestive heart failure (New York Heart Association class >= I)",
                                "criterion": "congestive heart failure",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "history of coronary artery disease",
                        "criterion": "history of coronary artery disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "chronic obstructive pulmonary disease",
                        "criterion": "chronic obstructive pulmonary disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: History of adverse event with a prior smallpox vaccination",
                "criterions": [
                    {
                        "exact_snippets": "History of adverse event with a prior smallpox vaccination",
                        "criterion": "adverse event with prior smallpox vaccination",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of adverse event with a prior smallpox vaccination",
                    "criterion": "adverse event with prior smallpox vaccination",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk",
                "criterions": [
                    {
                        "exact_snippets": "Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk",
                        "criterion": "patient condition posing infectious risk to study staff",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk",
                    "criterion": "patient condition posing infectious risk to study staff",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": false
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Females only: Pregnant or breastfeeding",
                "criterions": [
                    {
                        "exact_snippets": "Females only",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Females only",
                                "criterion": "sex",
                                "requirement": {
                                    "requirement_type": "value",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Pregnant",
                                        "criterion": "pregnancy status",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "breastfeeding",
                                        "criterion": "breastfeeding status",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).",
                "criterions": [
                    {
                        "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                        "criterion": "ability to comply with study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in the opinion of the investigator",
                        "criterion": "investigator's opinion on compliance",
                        "requirement": {
                            "requirement_type": "investigator assessment",
                            "expected_value": "satisfactory"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                        "criterion": "ability to comply with study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in the opinion of the investigator",
                        "criterion": "investigator's opinion on compliance",
                        "requirement": {
                            "requirement_type": "investigator assessment",
                            "expected_value": "satisfactory"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: History of heart disease, e.g. previous treated arrhythmia or myocardial infarction",
                "criterions": [
                    {
                        "exact_snippets": "History of heart disease",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "previous treated arrhythmia",
                        "criterion": "arrhythmia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "previous treated arrhythmia",
                        "criterion": "arrhythmia",
                        "requirement": {
                            "requirement_type": "treatment_status",
                            "expected_value": "treated"
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of heart disease",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "previous treated arrhythmia",
                                "criterion": "arrhythmia",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "previous treated arrhythmia",
                                "criterion": "arrhythmia",
                                "requirement": {
                                    "requirement_type": "treatment_status",
                                    "expected_value": "treated"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "myocardial infarction",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Any previous SARS-CoV-2 vaccine",
                "criterions": [
                    {
                        "exact_snippets": "Any previous SARS-CoV-2 vaccine",
                        "criterion": "previous SARS-CoV-2 vaccine",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Any previous SARS-CoV-2 vaccine",
                    "criterion": "previous SARS-CoV-2 vaccine",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection",
                "criterions": [
                    {
                        "exact_snippets": "Known history of immunodeficiency virus (HIV)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hepatitis B ... infection",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hepatitis C infection",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known history of immunodeficiency virus (HIV)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hepatitis B ... infection",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hepatitis C infection",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired, or for which this study would pose a danger to him/herself or about which the P.I., in evaluating the subject for eligibility, determines that this exclusion is appropriate",
                "criterions": [
                    {
                        "exact_snippets": "Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired",
                        "criterion": "immunological impairment",
                        "requirement": {
                            "requirement_type": "suggested presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "condition ... for which this study would pose a danger to him/herself",
                        "criterion": "condition posing danger from study participation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "about which the P.I., in evaluating the subject for eligibility, determines that this exclusion is appropriate",
                        "criterion": "P.I. determination of appropriate exclusion",
                        "requirement": {
                            "requirement_type": "P.I. exclusion determination",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired",
                        "criterion": "immunological impairment",
                        "requirement": {
                            "requirement_type": "suggested presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "condition ... for which this study would pose a danger to him/herself",
                        "criterion": "condition posing danger from study participation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "about which the P.I., in evaluating the subject for eligibility, determines that this exclusion is appropriate",
                        "criterion": "P.I. determination of appropriate exclusion",
                        "requirement": {
                            "requirement_type": "P.I. exclusion determination",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Participants using investigational or licensed agents that may prevent or treat SARS-CoV-2 are excluded",
                "criterions": [
                    {
                        "exact_snippets": "Participants using investigational or licensed agents that may prevent or treat SARS-CoV-2 are excluded",
                        "criterion": "use of investigational or licensed agents that may prevent or treat SARS-CoV-2",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Participants using investigational or licensed agents that may prevent or treat SARS-CoV-2 are excluded",
                    "criterion": "use of investigational or licensed agents that may prevent or treat SARS-CoV-2",
                    "requirement": {
                        "requirement_type": "use",
                        "expected_value": false
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Clinically significant uncontrolled illness",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant uncontrolled illness",
                        "criterion": "uncontrolled illness",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Clinically significant uncontrolled illness",
                    "criterion": "uncontrolled illness",
                    "requirement": {
                        "requirement_type": "clinical significance",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns with clinical study procedures.",
                "criterions": [
                    {
                        "exact_snippets": "Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns with clinical study procedures.",
                        "criterion": "other condition contraindicating participation due to safety concerns",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns with clinical study procedures.",
                        "criterion": "other condition contraindicating participation due to safety concerns",
                        "requirement": {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns with clinical study procedures.",
                        "criterion": "other condition contraindicating participation due to safety concerns",
                        "requirement": {
                            "requirement_type": "safety concern with clinical study procedures",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns with clinical study procedures.",
                        "criterion": "other condition contraindicating participation due to safety concerns",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns with clinical study procedures.",
                        "criterion": "other condition contraindicating participation due to safety concerns",
                        "requirement": {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns with clinical study procedures.",
                        "criterion": "other condition contraindicating participation due to safety concerns",
                        "requirement": {
                            "requirement_type": "safety concern with clinical study procedures",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures",
                "criterions": [
                    {
                        "exact_snippets": "Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures",
                        "criterion": "other condition contraindicating participation due to safety concerns",
                        "requirement": {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures",
                        "criterion": "other condition contraindicating participation due to safety concerns",
                        "requirement": {
                            "requirement_type": "safety concern with clinical study procedures",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures",
                                "criterion": "other condition contraindicating participation due to safety concerns",
                                "requirement": {
                                    "requirement_type": "investigator judgment",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures",
                                "criterion": "other condition contraindicating participation due to safety concerns",
                                "requirement": {
                                    "requirement_type": "safety concern with clinical study procedures",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired, or for which this study would pose a danger to him/herself or about which the P.I., in evaluating the participant for eligibility, determines that this exclusion is appropriate.",
                "criterions": [
                    {
                        "exact_snippets": "Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired",
                        "criterion": "immunological impairment",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "condition ... for which this study would pose a danger to him/herself",
                        "criterion": "condition posing danger from study participation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "about which the P.I., in evaluating the participant for eligibility, determines that this exclusion is appropriate",
                        "criterion": "P.I. discretion for exclusion",
                        "requirement": {
                            "requirement_type": "P.I. exclusion decision",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired",
                        "criterion": "immunological impairment",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "condition ... for which this study would pose a danger to him/herself",
                        "criterion": "condition posing danger from study participation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "about which the P.I., in evaluating the participant for eligibility, determines that this exclusion is appropriate",
                        "criterion": "P.I. discretion for exclusion",
                        "requirement": {
                            "requirement_type": "P.I. exclusion decision",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Clinically significant uncontrolled illness",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant uncontrolled illness",
                        "criterion": "clinically significant uncontrolled illness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Clinically significant uncontrolled illness",
                    "criterion": "clinically significant uncontrolled illness",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": false
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Active infection requiring treatment",
                "criterions": [
                    {
                        "exact_snippets": "Active infection requiring treatment",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active infection requiring treatment",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "requires treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active infection requiring treatment",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active infection requiring treatment",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "requires treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Any MVA vaccine or poxvirus vaccine in the last 12 months;",
                "criterions": [
                    {
                        "exact_snippets": "Any MVA vaccine or poxvirus vaccine in the last 12 months",
                        "criterion": "MVA vaccine or poxvirus vaccine administration",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any MVA vaccine or poxvirus vaccine in the last 12 months",
                        "criterion": "MVA vaccine or poxvirus vaccine administration",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Treatment with medication for high cholesterol or other lipid abnormality. Prophylactic medication is acceptable",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with medication for high cholesterol or other lipid abnormality",
                        "criterion": "treatment with medication for high cholesterol or other lipid abnormality",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prophylactic medication is acceptable",
                        "criterion": "prophylactic medication",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Treatment with medication for high cholesterol or other lipid abnormality",
                                    "criterion": "treatment with medication for high cholesterol or other lipid abnormality",
                                    "requirement": {
                                        "requirement_type": "treatment status",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "not_criteria": {
                                        "exact_snippets": "Prophylactic medication is acceptable",
                                        "criterion": "prophylactic medication",
                                        "requirement": {
                                            "requirement_type": "acceptability",
                                            "expected_value": true
                                        }
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                "criterions": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                        "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study agent",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                        "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study agent",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: History of heart disease, e.g. previous treated arrhythmia or myocardial infarction",
                "criterions": [
                    {
                        "exact_snippets": "History of heart disease",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "previous treated arrhythmia",
                        "criterion": "arrhythmia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "previous treated arrhythmia",
                        "criterion": "arrhythmia",
                        "requirement": {
                            "requirement_type": "treatment_status",
                            "expected_value": "treated"
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of heart disease",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "previous treated arrhythmia",
                                "criterion": "arrhythmia",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "previous treated arrhythmia",
                                "criterion": "arrhythmia",
                                "requirement": {
                                    "requirement_type": "treatment_status",
                                    "expected_value": "treated"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "myocardial infarction",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Active infection requiring treatment",
                "criterions": [
                    {
                        "exact_snippets": "Active infection requiring treatment",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active infection requiring treatment",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "treatment_requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active infection requiring treatment",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active infection requiring treatment",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "treatment_requirement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Poxvirus vaccine in the last 12 months",
                "criterions": [
                    {
                        "exact_snippets": "Poxvirus vaccine in the last 12 months",
                        "criterion": "Poxvirus vaccine",
                        "requirement": {
                            "requirement_type": "administration_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Poxvirus vaccine in the last 12 months",
                        "criterion": "Poxvirus vaccine",
                        "requirement": {
                            "requirement_type": "administration_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Noncompliance",
                "criterions": [
                    {
                        "exact_snippets": "Noncompliance",
                        "criterion": "compliance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Noncompliance",
                        "criterion": "compliance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 60 days after the second and last dose of vaccine;",
                "criterions": [
                    {
                        "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 60 days after the second and last dose of vaccine",
                        "criterion": "use of medically effective birth control methods",
                        "requirement": {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 60 days after the second and last dose of vaccine",
                        "criterion": "use of medically effective birth control methods",
                        "requirement": {
                            "requirement_type": "duration of use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 60 days after the second and last dose of vaccine",
                        "criterion": "use of medically effective birth control methods",
                        "requirement": {
                            "requirement_type": "duration reference",
                            "expected_value": "after the second and last dose of vaccine"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 60 days after the second and last dose of vaccine",
                                    "criterion": "use of medically effective birth control methods",
                                    "requirement": {
                                        "requirement_type": "willingness to use",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 60 days after the second and last dose of vaccine",
                                    "criterion": "use of medically effective birth control methods",
                                    "requirement": {
                                        "requirement_type": "duration of use",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 60,
                                            "unit": "days"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 60 days after the second and last dose of vaccine",
                                    "criterion": "use of medically effective birth control methods",
                                    "requirement": {
                                        "requirement_type": "duration reference",
                                        "expected_value": "after the second and last dose of vaccine"
                                    }
                                }
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 60 days after the second and last dose of vaccine",
                        "criterion": "use of medically effective birth control methods",
                        "requirement": {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Females only: Pregnant or breastfeeding",
                "criterions": [
                    {
                        "exact_snippets": "Females only",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Females only",
                                "criterion": "sex",
                                "requirement": {
                                    "requirement_type": "value",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Pregnant",
                                        "criterion": "pregnancy status",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "breastfeeding",
                                        "criterion": "breastfeeding status",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 6 weeks after the second and last dose of vaccine",
                "criterions": [
                    {
                        "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 6 weeks after the second and last dose of vaccine",
                        "criterion": "use of medically effective birth control methods",
                        "requirement": {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 6 weeks after the second and last dose of vaccine",
                        "criterion": "use of medically effective birth control methods",
                        "requirement": {
                            "requirement_type": "duration of use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks after the second and last dose of vaccine"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 6 weeks after the second and last dose of vaccine",
                                    "criterion": "use of medically effective birth control methods",
                                    "requirement": {
                                        "requirement_type": "willingness to use",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "exact_snippets": "Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 6 weeks after the second and last dose of vaccine",
                                    "criterion": "use of medically effective birth control methods",
                                    "requirement": {
                                        "requirement_type": "duration of use",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 6,
                                            "unit": "weeks after the second and last dose of vaccine"
                                        }
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: History (suspected or confirmed) of myocarditis or pericarditis",
                "criterions": [
                    {
                        "exact_snippets": "History (suspected or confirmed) of myocarditis",
                        "criterion": "myocarditis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History (suspected or confirmed) of ... pericarditis",
                        "criterion": "pericarditis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History (suspected or confirmed) of myocarditis",
                        "criterion": "myocarditis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History (suspected or confirmed) of ... pericarditis",
                        "criterion": "pericarditis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Participants who would be at higher risk for severe COVID-19 according to known risk factors are excluded e.g. type 2 diabetes, obesity (BMI > 35), congestive heart failure (New York Heart Association Class >= I), history of coronary artery disease, cardiomyopathies, sickle cell disease, smoking, chronic kidney disease, immunocompromised state from solid organ transplant, or chronic obstructive pulmonary disease, or active cancers other than basal cell skin cancer at discretion of the investigator.",
                "criterions": [
                    {
                        "exact_snippets": "type 2 diabetes",
                        "criterion": "type 2 diabetes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "obesity (BMI > 35)",
                        "criterion": "obesity",
                        "requirement": {
                            "requirement_type": "BMI",
                            "expected_value": {
                                "operator": ">",
                                "value": 35,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "obesity (BMI > 35)",
                        "criterion": "obesity",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure (New York Heart Association Class >= I)",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure (New York Heart Association Class >= I)",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "history of coronary artery disease",
                        "criterion": "coronary artery disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "cardiomyopathies",
                        "criterion": "cardiomyopathies",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "sickle cell disease",
                        "criterion": "sickle cell disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "smoking",
                        "criterion": "smoking",
                        "requirement": {
                            "requirement_type": "current or past use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "chronic kidney disease",
                        "criterion": "chronic kidney disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "immunocompromised state from solid organ transplant",
                        "criterion": "immunocompromised state from solid organ transplant",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "chronic obstructive pulmonary disease",
                        "criterion": "chronic obstructive pulmonary disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "active cancers other than basal cell skin cancer at discretion of the investigator",
                        "criterion": "active cancers (excluding basal cell skin cancer)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "active cancers other than basal cell skin cancer at discretion of the investigator",
                        "criterion": "active cancers (excluding basal cell skin cancer)",
                        "requirement": {
                            "requirement_type": "investigator discretion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "type 2 diabetes",
                            "criterion": "type 2 diabetes",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "obesity (BMI > 35)",
                            "criterion": "obesity",
                            "requirement": {
                                "requirement_type": "BMI",
                                "expected_value": {
                                    "operator": ">",
                                    "value": 35,
                                    "unit": ""
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "obesity (BMI > 35)",
                            "criterion": "obesity",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "congestive heart failure (New York Heart Association Class >= I)",
                            "criterion": "congestive heart failure",
                            "requirement": {
                                "requirement_type": "NYHA class",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 1,
                                    "unit": ""
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "congestive heart failure (New York Heart Association Class >= I)",
                            "criterion": "congestive heart failure",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "history of coronary artery disease",
                            "criterion": "coronary artery disease",
                            "requirement": {
                                "requirement_type": "history",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "cardiomyopathies",
                            "criterion": "cardiomyopathies",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "sickle cell disease",
                            "criterion": "sickle cell disease",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "smoking",
                            "criterion": "smoking",
                            "requirement": {
                                "requirement_type": "current or past use",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "chronic kidney disease",
                            "criterion": "chronic kidney disease",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "immunocompromised state from solid organ transplant",
                            "criterion": "immunocompromised state from solid organ transplant",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "chronic obstructive pulmonary disease",
                            "criterion": "chronic obstructive pulmonary disease",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "not_criteria": {
                                    "exact_snippets": "active cancers other than basal cell skin cancer at discretion of the investigator",
                                    "criterion": "active cancers (excluding basal cell skin cancer)",
                                    "requirement": {
                                        "requirement_type": "presence",
                                        "expected_value": false
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "not_criteria": {
                                            "exact_snippets": "active cancers other than basal cell skin cancer at discretion of the investigator",
                                            "criterion": "active cancers (excluding basal cell skin cancer)",
                                            "requirement": {
                                                "requirement_type": "investigator discretion",
                                                "expected_value": true
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: History of stroke or claudication",
                "criterions": [
                    {
                        "exact_snippets": "History of stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "claudication",
                        "criterion": "claudication",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "claudication",
                        "criterion": "claudication",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Systemic corticosteroids required for chronic conditions at doses > 0.5 mg/kg/day prednisone equivalent within 14 days of enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Systemic corticosteroids required for chronic conditions at doses > 0.5 mg/kg/day prednisone equivalent within 14 days of enrollment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "indication",
                            "expected_value": "chronic conditions"
                        }
                    },
                    {
                        "exact_snippets": "Systemic corticosteroids required for chronic conditions at doses > 0.5 mg/kg/day prednisone equivalent within 14 days of enrollment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 0.5,
                                "unit": "mg/kg/day prednisone equivalent"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Systemic corticosteroids required for chronic conditions at doses > 0.5 mg/kg/day prednisone equivalent within 14 days of enrollment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 14 days of enrollment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Systemic corticosteroids required for chronic conditions at doses > 0.5 mg/kg/day prednisone equivalent within 14 days of enrollment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "indication",
                            "expected_value": "chronic conditions"
                        }
                    },
                    {
                        "exact_snippets": "Systemic corticosteroids required for chronic conditions at doses > 0.5 mg/kg/day prednisone equivalent within 14 days of enrollment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 0.5,
                                "unit": "mg/kg/day prednisone equivalent"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Systemic corticosteroids required for chronic conditions at doses > 0.5 mg/kg/day prednisone equivalent within 14 days of enrollment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 14 days of enrollment"
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* PHASE II: Prior COVID-19 mRNA vaccination with EUA or FDA-approved vaccine, >= 6 months prior",
                "criterions": [
                    {
                        "exact_snippets": "Prior COVID-19 mRNA vaccination with EUA or FDA-approved vaccine",
                        "criterion": "COVID-19 mRNA vaccination",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "EUA-approved",
                                "FDA-approved"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Prior COVID-19 mRNA vaccination with EUA or FDA-approved vaccine",
                        "criterion": "COVID-19 mRNA vaccination",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": ">= 6 months prior",
                        "criterion": "time since COVID-19 mRNA vaccination",
                        "requirement": {
                            "requirement_type": "duration_since_vaccination",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* If positive, hepatitis C RNA quantitation must be performed",
                "criterions": [
                    {
                        "exact_snippets": "If positive, hepatitis C RNA quantitation must be performed",
                        "criterion": "hepatitis C RNA quantitation",
                        "requirement": {
                            "requirement_type": "requirement for testing",
                            "expected_value": "if hepatitis C is positive, then hepatitis C RNA quantitation must be performed"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "If positive, hepatitis C RNA quantitation must be performed",
                    "criterion": "hepatitis C",
                    "requirement": {
                        "requirement_type": "status",
                        "expected_value": "positive"
                    }
                },
                "then_criteria": {
                    "exact_snippets": "If positive, hepatitis C RNA quantitation must be performed",
                    "criterion": "hepatitis C RNA quantitation",
                    "requirement": {
                        "requirement_type": "requirement for testing",
                        "expected_value": true
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed",
                "criterions": [
                    {
                        "exact_snippets": "If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed",
                        "criterion": "hepatitis C ribonucleic acid (RNA) quantitation",
                        "requirement": {
                            "requirement_type": "requirement for testing",
                            "expected_value": "must be performed if positive"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed",
                    "criterion": "hepatitis C status",
                    "requirement": {
                        "requirement_type": "test result",
                        "expected_value": "positive"
                    }
                },
                "then_criteria": {
                    "exact_snippets": "If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed",
                    "criterion": "hepatitis C ribonucleic acid (RNA) quantitation",
                    "requirement": {
                        "requirement_type": "requirement for testing",
                        "expected_value": "must be performed"
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",
                "criterions": [
                    {
                        "exact_snippets": "urine test is positive or cannot be confirmed as negative",
                        "criterion": "urine pregnancy test result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": [
                                "positive",
                                "cannot be confirmed as negative"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "a serum pregnancy test will be required",
                        "criterion": "serum pregnancy test",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Ability to read and understand English, Spanish, or Mandarin for consenting",
                "criterions": [
                    {
                        "exact_snippets": "Ability to read and understand English, Spanish, or Mandarin for consenting",
                        "criterion": "language proficiency",
                        "requirement": {
                            "requirement_type": "languages",
                            "expected_value": [
                                "English",
                                "Spanish",
                                "Mandarin"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Ability to read and understand English, Spanish, or Mandarin for consenting",
                        "criterion": "language proficiency",
                        "requirement": {
                            "requirement_type": "ability to read and understand",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Women of childbearing potential (WOCBP)",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Women of childbearing potential (WOCBP)",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "negative urine or serum pregnancy test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "test type",
                            "expected_value": [
                                "urine pregnancy test",
                                "serum pregnancy test"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "negative urine or serum pregnancy test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "negative urine or serum pregnancy test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to day 0 of protocol therapy"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "Women of childbearing potential (WOCBP)",
                        "criterion": "sex and reproductive potential",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Women of childbearing potential (WOCBP)",
                        "criterion": "sex and reproductive potential",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "negative urine or serum pregnancy test (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "test type",
                            "expected_value": [
                                "urine",
                                "serum"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "negative urine or serum pregnancy test (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "negative urine or serum pregnancy test (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to day 0 of protocol therapy"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: A documented electrocardiogram (ECG) and cardiac troponin must be within normal institutional limits in the past 30 days; \"normal ECG with sinus tachycardia\" or \"normal ECG with sinus bradycardia\" is allowable based on a history of absent cardiac/exercise related symptoms as determined by the principal investigator (P.I.) in consultation with a senior staff cardiologist (within 30 days prior to day 0 of protocol therapy unless otherwise stated)",
                "criterions": [
                    {
                        "exact_snippets": "A documented electrocardiogram (ECG) ... must be within normal institutional limits in the past 30 days",
                        "criterion": "electrocardiogram (ECG) result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "within normal institutional limits"
                        }
                    },
                    {
                        "exact_snippets": "A documented electrocardiogram (ECG) ... must be within normal institutional limits in the past 30 days",
                        "criterion": "electrocardiogram (ECG) result",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "cardiac troponin must be within normal institutional limits in the past 30 days",
                        "criterion": "cardiac troponin level",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "within normal institutional limits"
                        }
                    },
                    {
                        "exact_snippets": "cardiac troponin must be within normal institutional limits in the past 30 days",
                        "criterion": "cardiac troponin level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "\"normal ECG with sinus tachycardia\" or \"normal ECG with sinus bradycardia\" is allowable based on a history of absent cardiac/exercise related symptoms as determined by the principal investigator (P.I.) in consultation with a senior staff cardiologist",
                        "criterion": "ECG with sinus tachycardia or sinus bradycardia",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": [
                                "normal ECG with sinus tachycardia",
                                "normal ECG with sinus bradycardia"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "\"normal ECG with sinus tachycardia\" or \"normal ECG with sinus bradycardia\" is allowable based on a history of absent cardiac/exercise related symptoms as determined by the principal investigator (P.I.) in consultation with a senior staff cardiologist",
                        "criterion": "ECG with sinus tachycardia or sinus bradycardia",
                        "requirement": {
                            "requirement_type": "symptom history",
                            "expected_value": "absent cardiac/exercise related symptoms"
                        }
                    },
                    {
                        "exact_snippets": "\"normal ECG with sinus tachycardia\" or \"normal ECG with sinus bradycardia\" is allowable based on a history of absent cardiac/exercise related symptoms as determined by the principal investigator (P.I.) in consultation with a senior staff cardiologist",
                        "criterion": "ECG with sinus tachycardia or sinus bradycardia",
                        "requirement": {
                            "requirement_type": "determination",
                            "expected_value": "as determined by the principal investigator in consultation with a senior staff cardiologist"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* PHASE I: Anyone considered to be in a vulnerable population as defined in 45 CFR 46.111 (a)(3) and 45 CFR 46, Subparts B-D",
                "criterions": [
                    {
                        "exact_snippets": "Anyone considered to be in a vulnerable population as defined in 45 CFR 46.111 (a)(3) and 45 CFR 46, Subparts B-D",
                        "criterion": "vulnerable population status",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Anyone considered to be in a vulnerable population as defined in 45 CFR 46.111 (a)(3) and 45 CFR 46, Subparts B-D",
                        "criterion": "vulnerable population status",
                        "requirement": {
                            "requirement_type": "definition_reference",
                            "expected_value": [
                                "45 CFR 46.111 (a)(3)",
                                "45 CFR 46, Subparts B-D"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Participants at increased risk of exposure to SARS-CoV-2, such as patient-facing health care workers and emergency responders are excluded",
                "criterions": [
                    {
                        "exact_snippets": "Participants at increased risk of exposure to SARS-CoV-2 ... are excluded",
                        "criterion": "risk of exposure to SARS-CoV-2",
                        "requirement": {
                            "requirement_type": "risk level",
                            "expected_value": "not increased"
                        }
                    },
                    {
                        "exact_snippets": "patient-facing health care workers and emergency responders are excluded",
                        "criterion": "occupation",
                        "requirement": {
                            "requirement_type": "occupation type",
                            "expected_value": [
                                "patient-facing health care worker",
                                "emergency responder"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "patient-facing health care workers and emergency responders are excluded",
                        "criterion": "occupation",
                        "requirement": {
                            "requirement_type": "inclusion",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Any of the following cardiac findings of ECG abnormality: 1) conduction disturbance (complete left or right bundle branch block, intraventricular conduction disturbance with QRS > 120 ms, atrioventricular block [AV] block of any degree, and corrected QT [QTc] prolongation > 450 msec for men and > 460 msec for women); 2) repolarization (ST segment or T wave) abnormality; 3) significant atrial or ventricular arrhythmia, including frequent ectopy (e.g., 2 premature ventricular contractions in a row); and 4) evidence of past myocardial infarction.",
                "criterions": [
                    {
                        "exact_snippets": "conduction disturbance (complete left or right bundle branch block, intraventricular conduction disturbance with QRS > 120 ms, atrioventricular block [AV] block of any degree",
                        "criterion": "cardiac conduction disturbance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "QRS > 120 ms",
                        "criterion": "QRS duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 120,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "corrected QT [QTc] prolongation > 450 msec for men and > 460 msec for women",
                        "criterion": "corrected QT interval (QTc)",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": [
                                "for men: > 450 msec",
                                "for women: > 460 msec"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "repolarization (ST segment or T wave) abnormality",
                        "criterion": "repolarization abnormality (ST segment or T wave)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "significant atrial or ventricular arrhythmia, including frequent ectopy (e.g., 2 premature ventricular contractions in a row)",
                        "criterion": "atrial or ventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "2 premature ventricular contractions in a row",
                        "criterion": "premature ventricular contractions (PVCs)",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": ">= 2 in a row"
                        }
                    },
                    {
                        "exact_snippets": "evidence of past myocardial infarction",
                        "criterion": "past myocardial infarction",
                        "requirement": {
                            "requirement_type": "evidence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Anyone considered to be in a vulnerable population as defined in 45 CFR §46.111 (a)(3) and 45 CFR §46, Subparts B-D",
                "criterions": [
                    {
                        "exact_snippets": "Anyone considered to be in a vulnerable population as defined in 45 CFR §46.111 (a)(3) and 45 CFR §46, Subparts B-D",
                        "criterion": "vulnerable population status",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Anyone considered to be in a vulnerable population as defined in 45 CFR \u0016746.111 (a)(3) and 45 CFR \u0016746, Subparts B-D",
                    "criterion": "vulnerable population status",
                    "requirement": {
                        "requirement_type": "exclusion",
                        "expected_value": false
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.",
                "criterions": [
                    {
                        "exact_snippets": "Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.",
                        "criterion": "daily medication use for chronic or intercurrent illness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.",
                        "criterion": "daily medication use for chronic or intercurrent illness",
                        "requirement": {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "thyroid replacement",
                                "estrogen replacement",
                                "dietary vitamins and protein supplements",
                                "mild anti-depressant and anxiety medication",
                                "any medication not known or likely to be immunosuppressive, as determined by the P.I."
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Participants who have had a live vaccine =< 30 days prior to administration of study vaccine or participants who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine). Flu shots are allowed > 2 weeks before the booster injection and > 2 weeks post booster injection",
                "criterions": [
                    {
                        "exact_snippets": "Participants who have had a live vaccine =< 30 days prior to administration of study vaccine",
                        "criterion": "live vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "participants who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine)",
                        "criterion": "inactivated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Participants who have had a live vaccine =< 30 days prior to administration of study vaccine",
                        "criterion": "live vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "participants who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine)",
                        "criterion": "inactivated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Participants who are employed by or are a student at City of Hope and are in a chain of command that reports directly to persons listed on the protocol as principal investigator or co-investigators; or are relatives or partners of the investigators",
                "criterions": [
                    {
                        "exact_snippets": "Participants who are employed by or are a student at City of Hope and are in a chain of command that reports directly to persons listed on the protocol as principal investigator or co-investigators",
                        "criterion": "employment or student status at City of Hope with direct reporting chain to protocol investigators",
                        "requirement": {
                            "requirement_type": "employment or student status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants who are employed by or are a student at City of Hope and are in a chain of command that reports directly to persons listed on the protocol as principal investigator or co-investigators",
                        "criterion": "employment or student status at City of Hope with direct reporting chain to protocol investigators",
                        "requirement": {
                            "requirement_type": "institution",
                            "expected_value": "City of Hope"
                        }
                    },
                    {
                        "exact_snippets": "Participants who are employed by or are a student at City of Hope and are in a chain of command that reports directly to persons listed on the protocol as principal investigator or co-investigators",
                        "criterion": "employment or student status at City of Hope with direct reporting chain to protocol investigators",
                        "requirement": {
                            "requirement_type": "chain of command",
                            "expected_value": "reports directly to principal investigator or co-investigators"
                        }
                    },
                    {
                        "exact_snippets": "are relatives or partners of the investigators",
                        "criterion": "relationship to investigators",
                        "requirement": {
                            "requirement_type": "relationship",
                            "expected_value": [
                                "relative",
                                "partner"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Participants who have had a live vaccine =< 30 days prior to administration of study vaccine or subjects who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine). Flu shots are allowed > 2 weeks before the first injection and > 2 weeks post 2nd injection",
                "criterions": [
                    {
                        "exact_snippets": "Participants who have had a live vaccine =< 30 days prior to administration of study vaccine",
                        "criterion": "live vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "subjects who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine)",
                        "criterion": "inactivated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Flu shots are allowed > 2 weeks before the first injection and > 2 weeks post 2nd injection",
                        "criterion": "influenza vaccine (flu shot) administration",
                        "requirement": {
                            "requirement_type": "time before first injection",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Flu shots are allowed > 2 weeks before the first injection and > 2 weeks post 2nd injection",
                        "criterion": "influenza vaccine (flu shot) administration",
                        "requirement": {
                            "requirement_type": "time after second injection",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Participants who have had a live vaccine =< 30 days prior to administration of study vaccine",
                        "criterion": "live vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "subjects who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine)",
                        "criterion": "inactivated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Flu shots are allowed > 2 weeks before the first injection and > 2 weeks post 2nd injection",
                        "criterion": "influenza vaccine (flu shot) administration",
                        "requirement": {
                            "requirement_type": "time before first injection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Flu shots are allowed > 2 weeks before the first injection and > 2 weeks post 2nd injection",
                        "criterion": "influenza vaccine (flu shot) administration",
                        "requirement": {
                            "requirement_type": "time after second injection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Persons listed on the protocol as Principal Investigator or Co-Investigators, and those who have disclosed a Conflict of Interest regarding COH04S1. Prospective participants who are COH employees reporting to study personnel conducting consent for the Phase 2 study must be consented by other consenting personnel to ensure no coercion. COH employees who would be involved in a quality or risk management function (auditing or monitoring) or the Study Management Team (SMT) with respect to this trial are ineligible.",
                "criterions": [
                    {
                        "exact_snippets": "Persons listed on the protocol as Principal Investigator or Co-Investigators",
                        "criterion": "role on protocol",
                        "requirement": {
                            "requirement_type": "role",
                            "expected_value": [
                                "Principal Investigator",
                                "Co-Investigator"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "those who have disclosed a Conflict of Interest regarding COH04S1",
                        "criterion": "conflict of interest regarding COH04S1",
                        "requirement": {
                            "requirement_type": "disclosure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "COH employees reporting to study personnel conducting consent for the Phase 2 study must be consented by other consenting personnel to ensure no coercion",
                        "criterion": "COH employee reporting to study personnel conducting consent",
                        "requirement": {
                            "requirement_type": "consent by other personnel",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "COH employees who would be involved in a quality or risk management function (auditing or monitoring) or the Study Management Team (SMT) with respect to this trial are ineligible",
                        "criterion": "COH employee involvement in quality or risk management function or SMT",
                        "requirement": {
                            "requirement_type": "involvement in quality or risk management function or SMT",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE I: Participants are excluded, who have any history of allergic diatheses as defined by a history of asthma, anaphylaxis, or generalized urticaria, or by daily use of antihistamines, episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium",
                "criterions": [
                    {
                        "exact_snippets": "history of allergic diatheses as defined by a history of asthma",
                        "criterion": "asthma",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of allergic diatheses as defined by a history of ... anaphylaxis",
                        "criterion": "anaphylaxis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of allergic diatheses as defined by a history of ... generalized urticaria",
                        "criterion": "generalized urticaria",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "daily use of antihistamines",
                        "criterion": "antihistamine use",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": "daily"
                        }
                    },
                    {
                        "exact_snippets": "episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium",
                        "criterion": "inhalational medication use",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "in past 3 months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium",
                        "criterion": "inhalational medication use",
                        "requirement": {
                            "requirement_type": "medication_type",
                            "expected_value": [
                                "steroidal agents",
                                "non-steroidal agents",
                                "cromolyn sodium"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Participants are excluded who have any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc. as determined by the P.I.)",
                "criterions": [
                    {
                        "exact_snippets": "any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study",
                        "criterion": "condition precluding informed consent, follow-up, or compliance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "untreated schizophrenia",
                        "criterion": "untreated schizophrenia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "other significant cognitive impairment",
                        "criterion": "significant cognitive impairment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "other significant cognitive impairment",
                        "criterion": "significant cognitive impairment",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study",
                        "criterion": "condition precluding informed consent, follow-up, or compliance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "untreated schizophrenia",
                        "criterion": "untreated schizophrenia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "other significant cognitive impairment",
                                "criterion": "significant cognitive impairment",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "significant"
                                }
                            },
                            {
                                "exact_snippets": "other significant cognitive impairment",
                                "criterion": "significant cognitive impairment",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.",
                "criterions": [
                    {
                        "exact_snippets": "Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.",
                        "criterion": "daily medication use for chronic or intercurrent illness",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.",
                        "criterion": "daily medication use for chronic or intercurrent illness",
                        "requirement": {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "thyroid replacement",
                                "estrogen replacement",
                                "dietary vitamins and protein supplements",
                                "mild anti-depressant and anxiety medication",
                                "any medication not known or likely to be immunosuppressive, as determined by the P.I."
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* PHASE II: Participants are excluded, who have any history of allergic diatheses as defined by a history of asthma, anaphylaxis, or generalized urticaria, episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium",
                "criterions": [
                    {
                        "exact_snippets": "history of allergic diatheses as defined by a history of asthma, anaphylaxis, or generalized urticaria",
                        "criterion": "allergic diatheses",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of asthma",
                        "criterion": "asthma",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of anaphylaxis",
                        "criterion": "anaphylaxis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of ... generalized urticaria",
                        "criterion": "generalized urticaria",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium",
                        "criterion": "inhalational medication use",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "in past 3 months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium",
                        "criterion": "inhalational medication use",
                        "requirement": {
                            "requirement_type": "medication_type",
                            "expected_value": [
                                "steroidal agents",
                                "non-steroidal agents",
                                "cromolyn sodium"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}